No Data
Zhejiang Zhenyuan: Zhejiang Zhenyuan Co., Ltd. 2024 Annual Performance Forecast
Zhejiang Zhenyuan Share (000705.SZ): Currently, there are no products produced for the treatment of influenza virus.
On January 10, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interactive platform that the company's Pharmaceutical Sector produces antibiotics and anti-inflammatory painkillers for upper respiratory bacterial infections, and currently does not produce products for the treatment of influenza virus. Customers can visit Zhenyuan's affiliated stores and online mall to purchase related Pharmaceuticals as needed.
Zhejiang Zhenyuan Share (000705.SZ): Not involved in the silver-haired industry.
On January 10, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interaction platform that the company's operation includes pharmaceutical distribution, pharmaceutical manufacturing, and health services, with the main business specifically consisting of the pharmaceutical commerce and pharmaceutical manufacturing sectors, and does not involve the silver industry.
Zhejiang Zhenyuan Share (000705.SZ): Currently, the biological project has launched the sterile culture linkage debugging.
Gelonghui reported on January 8 that Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interaction platform that Zhenyuan Bio originally planned to move up the Engineering & Construction completion date to December 2024 and begin trial production. However, due to some equipment installation progress not meeting expectations, the project construction has been delayed. Currently, the biological project has initiated sterile culture linkage debugging.
Zhejiang Zhenyuan Share (000705.SZ) plans to sign the "Capital Increase Agreement" with CHINARES PHARMA.
On December 24th, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) announced that it has carried out a capital increase by introducing strategic investors for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (referred to as "Zhenyuan Pharmaceuticals"), through a public listing at the Shaoxing Property Exchange. After review by the exchange and confirmation by the company, CHINARES PHARMA was determined to be the qualified investor for the capital increase, and a "Capital Increase Agreement" is planned to be signed with CHINARES PHARMA at a price of 1.439517 yuan per registered capital, with an increase amount of 119.8618235 million yuan.
Zhejiang zhenyuan share (000705.SZ) intends to introduce a leading pharmaceutical commerce company as a new shareholder for zhenyuan pharmaceutical, raising no less than approximately 0.12 billion yuan.
Zhejiang Zhenyuan (000705.SZ) announced that the company intends to engage in a transaction with the Shaoxing Property Rights Exchange (Zhejiang Exchange...)
Are Zhejiang Zhenyuan Share Co.,Ltd.'s (SZSE:000705) Mixed Financials Driving The Negative Sentiment?
